231
Participants
Start Date
April 1, 2015
Primary Completion Date
October 26, 2018
Study Completion Date
November 6, 2020
Inebilizumab
Participants will receive IV inebilizumab 300 mg.
Placebo
Participants will receive IV placebo matched to inebilizumab.
Research Site, Auckland
Research Site, Sofia
Research Site, Sofia
Research Site, Sofia
Research Site, Chisinau
Research Site, Esztergom
Research Site, Melbourne
Research Site, Nyíregyháza
Research Site, Szeged
Research Site, Cape Town
Research Site, Cape Town
Research Site, Varna
Research Site, Berlin
Research Site, Tallinn
Research Site, Bangkok
Research Site, Belgrade
Research Site, Mexico City
Research Site, Rostock
Research Site, Baltimore
Research Site, Richmond
Research Site, Raleigh
Research Site, Madrid
Research Site, Maitland
Research Site, Istanbul
Research Site, Istanbul
Research Site, Istanbul
Research Site, Izmir
Research Site, Birmingham
Research Site, Muang
Research Site, Düsseldorf
Research Site, Cleveland
Research Site, Mansfield
Research Site, Cincinnati
Research Site, Münster
Research Site, Detroit
Research Site, Changhua
Research Site, Muang
Research Site, Tartu
Research Site, Ramat Gan
Research Site, Samsun
Research Site, Rochester
Research Site, Chicago
Research Site, Novosibirsk
Research Site, Monterrey
Research Site, Kansas City
Research Site, Tainan City
Research Site, Dallas
Research Site, Houston
Research Site, San Luis Potosí City
Research Site, Aurora
Research Site, Jerusalem
Research Site, San Francisco
Research Site, Sacramento
Research Site, Hualien City
Research Site, Bogotá
Research Site, Bogotá
Research Site, Moscow
Research Site, Moscow
Research Site, Seoul
Research Site, Saint Petersburg
Research Site, Belgorod
Research Site, Kazan'
Research Site, Ufa
Research Site, Nizhny Novgorod
Research Site, Omsk
Research Site, Krasnoyarsk
Research Site, Khabarovsk
Research Site, Santiago de Cali
Research Site, Tel Aviv
Research Site, New Haven
Research Site, St Louis
Research Site, Vancouver
Research Site, Barranquilla
Research Site, Olomouc
Research Site, Prague
Research Site, Teplice
Research Site, Dresden
Research Site, Leipzig
Research Site, Hong Kong
Research Site, Aomori
Research Site, Bunkyō City
Research Site, Kyoto
Research Site, Ōta-ku
Research Site, Sendai
Research Site, Tsukuba
Research Site, Mexico City
Research Site, Bellavista
Research Site, Lima
Research Site, Katowice
Research Site, Krakow
Research Site, Lódz
Research Site, Lublin
Research Site, Olsztyn
Research Site, Warsaw
Research Site, Warsaw
Research Site, Goyang
Research Site, Jongno-gu
Research Site, Seoul
Lead Sponsor
MedImmune LLC
INDUSTRY